Jefferson Scientists Find Protein Potential Drug Target For Treatment-resistant Prostate Cancer

Scientists at Jefferson’s Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer. In addition, the researchers, led by Marja Nevalainen, M.D., Ph.D. [click link for full article]

More: continued here

Filed under: Prostate on January 1st, 2008